It was suggested by [41] that ACTB has at most a marginal role in sporadic hematologic carcinogenesis because a screening of 95 B-cell acute lymphoblastic leukemia (B-ALL) samples identified no ACTB mutations. The gene discussed is ACTB; the disease is B-cell acute lymphoblastic leukemia.